ACU193ACU193 is the first immunotherapy drug candidate to enter the clinic that was developed to selectively target toxic soluble amyloid beta oligomers (AβOs). As AβOs are an early trigger and persistent driver of Alzheimer’s-associated pathology and neurodegeneration, ACU193 addresses an underlying cause of Alzheimer’s by preventing toxic AβOs from binding to dendritic spines and helping preserve neuronal function. |
||||
8-yearcollaboration with Merck |
$3.6 millionAwarded a competitive $3.6 million U01 grant from National Institute of |
IPO
|
||
Phase 1Enrollment Complete |
Phase 2Planning |
Phase 3Planning |
SubmissionPlanning |
ApprovalPlanning |
INTERCEPT-AD (NCT04931459)
This study is a phase 1, randomized, single ascending dose (SAD) and multiple ascending dose (MAD), placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous ACU193 when administered to participants diagnosed with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease